Chapter-8 References

NIMS Institute of Pharmacy, NIMS University Jaipur Page 80

REFERENCES:-

1. Chien YW, 1992,. “Novel drug delivery systems”, 2nd Edition; Marcel

Dekker Inc: New York, 139-40.

2. Wani M., 2008, “Controlled Released System - A Review”,

Pharmainfo.net , Vol. 6, Issue 1,.

3. Hui HW, Robinson JR, Lee VHL. “Design and fabrication of oral

controlled release drug delivery systems”. In: Robinson JR, Lee V, editors.

Controlled drug delivery fundamentals and applications. 2nd

Ed.; Marcel

Dekker: New York: Inc; p. 373-4.

4. Jantzen GM, Robinson JR, 1996, “Sustained- and controlled-release drug

delivery systems.” In: Banker GS, Rhodes CT, editors. Modern

pharmaceutics. 3rd

Ed.; Marcel Dekker Inc; New York; 575-609.

Gudsoorkar VR, Rambhau D., 1993, “Extended release of drugs”. The

Eastern Pharmacist, 36(429); 17-22.

5. Lachman L, Lieberman HA, Kanig JL., 1987, “The theory and practice of

industrial pharmacy”, 3rd

Ed.; Varghese Publishing House Bombay, 293-

345,430.

6. Remington: The science and Practice of Pharmacy., 19th

Ed.; 1660, 1676,

1995.

7. Robinson J. R. Lee L. H., 1987, “Controlled Drug Delivery: Fundamentals

and Applications”, 2nd

Ed. 29, 312-319.

8. Alderman D. A., 1984, “International Journal of Pharmaceutical

Technology and Product Manufacture”. , 1(5).

9. M Flu Lu et al, 1991, “Drug Dev. Ind. Pharm”, 17(4), 1987-2004,.

10. Nigayale A. G. et al. , 1990, “Drug Dev. Ind. Pharm” 16, 2-8.

11. Pandey V., Manavalan R., Rajan T. et al, 2003, “Formulation and release

characteristics of Extended release diltiazem hydrochloride tablet”, Indian

Journal of Pharmaceutical Science , 65(1):44-8.

12. Hoffman A., 1998, “Pharmacodynamic aspects of Extended release

preparations”, Adv Drug Del Rev, 33: 185-99.

13. Jain NK, 2002, “Controlled and novel drug delivery”, 1st Ed.; CBS

Publishers; New Delhi

Chapter-8 References

NIMS Institute of Pharmacy, NIMS University Jaipur Page 81

14. Yie W, Chien, 2005, “Rate controlled drug delivery systems.” 2nd

Ed.

Marcel Dekker; New York, Revised and expanded,.

15. Jose G., Hossein O, Khalid S, 2003, “Progress in gastroretentive drug

delivery systems. Solid dose research and development”, Pharmatech, 152-

56.

16. Jaber E, Naser D, 2004, “Formulation of sustrained release lithium

carbonate matrix tablets: influence of hydrophilic materials on the release

rate and in vitro – in vivo evaluation”, Journal Pharmaceutical Science, 7:

338-44.

17. Aditya ST, Ketan AM, Larry LA, Stephen WH, 2004, “Influence of

methacrylic and acrylic acid polymers on the release performance of

weakly basic drugs from Extended release hydrophilic matrix”, Journal

Pharmaceutical Science.,93,2319-31.

18. Chowhan ZT. Role of binders in moisture-induced hardness increase in

compressed tablets and its effect on in vitro disintegration and dissolution.

J Pharm Sci 1980; 69: 1–4.

19. Rowe RC. The adhesion of film coatings to tablet surfaces – the effect of

some direct compression excipients and lubricants. J Pharm Pharmacol

1977; 29: 723–726.

20. Rowe RC. The molecular weight and molecular weight distribution of

hydroxypropyl methylcellulose used in the film coating of tablets. J Pharm

Pharmacol 1980; 32: 116–119.

21. Banker G, Peck G, Jan S, Pirakitikulr P. Evaluation of hydroxypropyl

cellulose and hydroxypropyl methyl cellulose as aqueous based film

coatings. Drug Dev Ind Pharm 1981; 7: 693–716.

22. Okhamafe AO, York P. Moisture permeation mechanism of some aqueous-

based film coats. J Pharm Pharmacol 1982; 34 (Suppl.): 53P.

23. Alderman DA, Schulz GJ. Method of making a granular, cold water

dispersible coating composition for tablets. United States Patent No.

4,816,298; 1989.

24. Patell MK. Taste masking pharmaceutical agents. United States Patent No.

4,916,161; 1990.

Chapter-8 References

NIMS Institute of Pharmacy, NIMS University Jaipur Page 82

25. Hardy JG, Kennerley JW, Taylor MJ, et al. Release rates from sustained-

release buccal tablets in man. J Pharm Pharmacol 1982; 34 (Suppl.): 91P.

26. Hogan JE. Hydroxypropylmethylcellulose sustained release technology.

Drug Dev Ind Pharm 1989; 15: 975–999.

27. Shah AC, Britten NJ, Olanoff LS, Badalamenti JN. Gel-matrix systems

exhibiting bimodal controlled release for oral delivery. J Control Release

1989; 9: 169–175.

28. Wilson HC, Cuff GW. Sustained release of isomazole from matrix tablets

administered to dogs. J Pharm Sci 1989; 78: 582–584.

29. Dahl TC, Calderwood T, Bormeth A, et al. Influence of physicochemical

properties of hydroxypropyl methylcellulose on naproxen release from

sustained release matrix tablets. J Control Release 1990; 14: 1–10.

30. Banker G, Peck G, Williams E, et al. Microbiological considerations of

polymer solutions used in aqueous film coating. Drug Dev Ind Pharm

1982; 8: 41–51.

31. Anonymous. Final report on the safety assessment of

hydroxyethylcellulose, hydroxypropylcellulose, methylcellulose,

hydroxypropyl methylcellulose and cellulose gum. J Am Coll Toxicol

1986; 5(3): 1–60.

32. FAO/WHO. Evaluation of certain food additives and contaminants. Thirty-

fifth report of the joint FAO/WHO expert committee on food additives.

World Health Organ Tech Rep Ser 1990; No. 789.

33. Lewis RJ, ed. Sax’s Dangerous Properties of Industrial Materials, 11th

edn. New York: Wiley, 2004: 2054.

34. UCB (2007-11-29). "UCB Announces FDA Filing for drug-x in the

Treatment of Diabetic Neuropathic Pain". Press release. Retrieved 2007-

11-29

35. National Society for Epilepsy. Epilepsy: Information on epileptic

seizures.Available

at:http://www.epilepsynse.org.uk/PAGES/whatsnew/pr/ep_facts.cfm

[Accessed 15 August 2008].

Chapter-8 References

NIMS Institute of Pharmacy, NIMS University Jaipur Page 83

36. Ben-Menachem, E. Lacosamide: an investigational drug for adjunctive

treatment of partial-onset seizures. Drugs of Today 2007; 43 Available at:

www.prous.com/journals

37. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000506/

38. Gupta s., Kapoor V., Kapoor B., Itopride: A Novel Prokinetic agent; JK

Science A Drug Review; 2004; 6(2); 106-108.

39. Mcquaid KR., Dyspepsia. In: Mark Feldman et al (eds.), Sleisenger &

Fordtran's Gastrointestinal and Liver Disease

Pathophysiology/Diagnosis/Management.7th edition 2002; 1; 102-18.

40. Pasricha PJ., Prokinetic agents, antiemetics agents used in irritable bowel

syndrome. In: Hardman JG et al (eds.), Goodman and Gilman'ss The

Pharmacological Basis of Therapeutics, 10th edition, New York, McGraw

Hill Book Inc.; 2001; 1021.

41. Wysowski DK., Corken A., Gallo TH et al. Post-marketing reports of QT

prolongation & ventricular arrhythmias in association with cisapride and

food and Drug administration regulatory actions; American Journal of

Gastroenterology; 2001; 96; 1698-1703.

42. Mushiroda T., Douya R., Takahara E., Nagata O., The involvement of

flavin containing monooxygenase but not CYP3A4 in metabolism

of itopride hydrochloride, a gastrokinetic agent: comparison with cisapride

and Mosapride citrate. Drug Metab Dispos 2000; 28: 1231-37.

43. Gupta s., Kapoor V., Kapoor B., Itopride: A Novel Prokinetic agent; JK

Science A Drug Review; 2004; 6(2); 106-108.

44. Mcquaid KR., Dyspepsia. In: Mark Feldman et al (eds.), Sleisenger &

Fordtran's Gastrointestinal and Liver Disease

Pathophysiology/Diagnosis/Management.7th edition 2002; 1; 102-18.

45. Pasricha PJ., Prokinetic agents, antiemetics agents used in irritable bowel

syndrome. In: Hardman JG et al (eds.), Goodman and Gilman'ss The

Pharmacological Basis of Therapeutics, 10th edition, New York, McGraw

Hill Book Inc.; 2001; 1021.

46. Wysowski DK., Corken A., Gallo TH et al. Post-marketing reports of QT

prolongation & ventricular arrhythmias in association with cisapride and

Chapter-8 References

NIMS Institute of Pharmacy, NIMS University Jaipur Page 84

food and Drug administration regulatory actions; American Journal of

Gastroenterology; 2001; 96; 1698-1703.

47. Mushiroda T., Douya R., Takahara E., Nagata O., The involvement of

flavin containing monooxygenase but not CYP3A4 in metabolism

of itopride hydrochloride, a gastrokinetic agent: comparison with cisapride

and Mosapride citrate. Drug Metab Dispos 2000; 28: 1231-37.

48. http://www.symedlabs.com/p6.htm

49. Kibbe AH., Handbook of pharmaceutical excipients; American

Pharmaceutical Association and Pharmaceutical Press, Washington

London; 2000; 3rd Ed; 102-106.

50. Lachman L., Lieberman HA., Kanig JL., The theory and practice of

Industrial pharmacy, Varghese Publishing House Bombay; 1987; 171-293.

51. Aulton ME., The Science of dosage form design; Churchill living stone;

2002; 2nd edition; 414-418.

52. Cooper J, Gun C, Powder Flow and Compaction. Inc Carter SJ, Eds.

Tutorial Pharmacy. New Delhi, hidix CBS Publishers and Distributors;

1986:211-233.

53. Martin A, Micromeretics, In: Martin A, ed. Physical Pharmacy.Baltimores,

MD: Lippincott Williams and Wilkins; 2001:423-454.

54. ICH topic 8 Pharmaceutical guidelines, Note for Guidance on

Pharmaceutical Developments, (EMEA/CHMP167068/2004).

55. Baertschi, S. W., Pharmaceutical stress testing, predicting drug

degradation, Taylor and Francis group, 2005, 344-350.

56. The Indian Pharmacopoeia; Ministry of Health and Family Welfare,

Government of India, Controller of Publications, New Delhi; 1996; 4th

Edition; Volume II.

57. Moore JW., Flanner HH., Mathematical comparison of curves with an

emphasis on in-vitro dissolution profiles; Pharmaceutical Technology;

1996; 20(6); 64-74.

58. Paulo C., Jose Manuel, Sousa L., Modeling and comparison of dissolution

profiles; European Journal of Pharmaceutical Science; 2001; 13; 123-133.

Chapter-8 References

NIMS Institute of Pharmacy, NIMS University Jaipur Page 85

59. Korsmeyer RW., Peppas NA., Effect of the morphology of hydrophilic

polymeric matrices on the diffusion and release of water soluble drugs,

Journal of Membr. Science; 1981; 9; 211–227.

60. Higuchi T., Mechanism of sustained action medication, Theoretical

analysis of rate release of solid drugs dispersed in solid matrices; Journal

of Pharmaceutical Science; 1963; 52; 1145-1149.

61. ICH GUIDELINES Q1A (R2), Guidance for industry, stability testing of

new drug substance and products (Available on: http://

http://www.ich.org).